Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Three-year outcomes from prospective, randomized study of micro-invasive glaucoma surgery (MIGS) with two trabecular stents vs one prostaglandin in newly diagnosed open-angle glaucoma

Poster Details

First Author: G. Auffarth GERMANY

Co Author(s):                        

Abstract Details


Recent findings by the Micro-Invasive Glaucoma Surgery (MIGS) Study Group showed IOP control through 2 years following treatment with either 2 trabecular bypass stents or medical therapy in a prospective, randomized controlled study in patients with newly diagnosed glaucoma naïve to treatment. This work provides follow-up data through 3 years in the same set of study subjects.


The MIGS Study Group consists of visiting surgeons and staff surgeons from eight countries worldwide. Surgeons have performed MIGS procedures at one investigational setting – the S.V. Malayan Ophthalmological Center in Yerevan, Armenia.


Study qualification criteria included IOP ≥ 21 mmHg and ≤ 40mmHg, and CD ratio ≤ 0.9. Eyes were randomized 1:1 to either implantation of two trabecular stents (iStent® Trabecular Micro-Bypass, Glaukos Corporation; n = 54) or to administration of travoprost (n=48). Following treatment, medication was to be added to study eyes in either group for elevated IOP (e.g., IOP > 21 mmHg) or for optic nerve findings. Clinical parameters before treatment and through up to 5 years post-treatment included IOP, medication use, treatment and post-treatment complications, BCVA, slit-lamp exam, fundus/optic nerve exam, gonioscopy, visual field and CD ratio.


In stent-implanted eyes, IOP reduced from 25.5 mmHg preoperatively to 14.6 mmHg at 3 years. No complications were reported during implantation of stents. In travoprost-treated eyes, IOP decreased from 25.0 mmHg before treatment to 15.3 mmHg at 3 years. By the 3-year exam, 6 stent eyes and 11 travoprost eyes in had medical therapy added to their original treatment. Over the 3-year follow-up period, progression of cataract was observed in 11 stent-implanted eyes and 8 travoprost-treated eyes, with cataract surgery performed in 5 stent eyes and 1 travoprost eye. No other post-treatment adverse events were reported.BCVA appeared stable over time.


Follow-up data through 3 years from a prospective, randomized study to treat newly diagnosed OAG with either implantation of 2 trabecular micro-bypass stents or travoprost showed substantial decrease in IOP in both groups. These data suggest that 2 trabecular stents or prostaglandin offer IOP control with a favorable safety profile through 3 years in this patient population.

Financial Disclosure:

One or more of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing